Angiogenesis in chronic myeloproliferative diseases

Acta Haematologica

Volumn 106, Issue 4, 2001, Pages 177-183

  Di Raimondo, Francesco ^a,c   Palumbo, Giuseppe A ^a   Molica, Stefano ^b   Giustolisi, Rosario ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b PUGLIESE CIACCIO HOSPITAL   (Italy)

^c Ospedale Ferrarotto   (Italy)

Author keywords

Angiogenesis; Chronic myeloid leukemia; Essential thrombocythemia; Myelofibrosis; Polycythemia vera

Indexed keywords

HYDROXYUREA; INTERFERON; SCATTER FACTOR; THALIDOMIDE; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; BLOOD LEVEL; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; DRUG ACTIVITY; HUMAN; MEGAKARYOCYTE; MYELOFIBROSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; THROMBOCYTHEMIA; THROMBOCYTOSIS;

BONE MARROW; CHRONIC DISEASE; GROWTH SUBSTANCES; HUMANS; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDERS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0035706649     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000046614     Document Type: Article

References (32)

1. Tumor vascularity as a prognostic factor in cancer
2. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia
3. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma
4. Vascular architecture and collagen type IV in primary myelofibrosis and polycythaemia vera: An immunomorphometric study on trephine biopsies of the bone marrow
5. Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity
6. Evaluation and clinical correlations of microvessel density in myelofibrosis with myeloid metaplasia
7. Myelofibrosis with myeloid metaplasia: Diagnostic definition and prognostic classification for clinical studies and treatment guidelines
8. Myelofibrosis with myeloid metaplasia
9. Investigation of calmodulin and basic fibroblast growth factor (bFGF) in idiopathic myelofibrosis: Evidence for a role of extracellular calmodulin in fibroblast proliferation
10. Differential expression of transforming growth factor-β, basic fibroblast growth factor, and their receptors in CD34+ hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia
11. Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis
12. Quantification of angiogenesis in solid human tumors: An international consensus on the methodology and criteria of evaluation
13. Biology of vascular endothelial growth factor
14. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vitro
15. Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis
16. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets
17. KDR receptor: A key marker defining hematopoietic stem cells
18. Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implication in cancer
19. Thalidomide anti-angiogenesis therapy (RX) in Philadelphia (Ph)-negative myeloproliferative disorders (MPD) and myelofibrosis (MF)
20. Vascular density, intracellular VEGF and bFGF positivity as prognostic factors in polycythemia vera and chronic myelocytic leukemia
21. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes
22. Role of vascular endothelial growth factor (VEGF) and placenta-derived growth factor (PLGF) in regulating human haemopoietic cell growth
23. Chronic myelogenous leukemia (CML) cells stimulate angiogenesis
24. Low serum levels of vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in IFN-treated chronic myeloid leukemia (CML) patients
25. Angiogenesis in acute myeloid leukemia
26. Angiogenesis in chronic myeloproliferative disorders
27. Bone marrow immunohistochemical features complement histology in distinguishing essential thrombocythemia from reactive thrombocytosis
28. Clinical correlates of megakaryocyte c-mpl expression in essential thrombocythemia: A clinicopathologic study of 169 patients
29. Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: A key to study an angiogenic marker in vivo?
30. Current status of antiangiogenic factors
31. The thin red line: Angiogenesis in normal and malignant hematopoiesis
32. The hallmarks of cancer